Budesonide/formoterol - Teva Pharmaceutical Industries

Drug Profile

Budesonide/formoterol - Teva Pharmaceutical Industries

Alternative Names: BF Spiromax®; BiResp Spiromax; Budesonide/formoterol - Teva; Budesonide/formoterol Spiromax®; DuoResp Spiromax; Formoterol/budesonide - Teva; Vylaer Spiromax

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Teva Pharmaceutical Industries
  • Class Antiasthmatics; Bronchodilators; Ethanolamines; Glucocorticoids; Pregnenediones; Small molecules
  • Mechanism of Action Beta 2 adrenergic receptor agonists; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Asthma; Chronic obstructive pulmonary disease

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
  • 31 Dec 2014 Launched for Asthma (In adults) in Spain (Inhalation)
  • 31 Dec 2014 Launched for Chronic obstructive pulmonary disease (In adults) in Spain (Inhalation)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top